Completed PHASE2 INTERVENTIONAL NCT00158509

Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding

Efficacy of an HSV2 Genital Herpes Suppressive Treatment on HIV and HSV2 Genital Shedding Among Co-Infected Patients Receiving or Not Antiretroviral Drugs

Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Conditions HIV Infection Herpes Genitalis

Interventions Valacyclovir

Updated 5 times since 2017 Last updated: Jun 6, 2006 Started: Aug 31, 2004 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on HIV Infection and Herpes Genitalis, this trial is completed. The trial is conducted by French National Agency for Research on AIDS and Viral Hepatitis and has accumulated 5 data snapshots since 2004. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

French National Agency for Research on AIDS and Viral Hepatitis

Data source: French National Agency for Research on AIDS and Viral Hepatitis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bobo-Dioulasso, Burkina Faso